莫西沙星注射液与左氧氟沙星注射液随机对照治疗社区获得性肺炎药物经济学评价

目的评价莫西沙星注射液与左氧氟沙星注射液治疗社区获得性肺炎安全性﹑有效性并对两组的医疗费用进行药物经济学评价。方法采用区组随机、开放、平行对照设计方法;各种社区获得性肺炎符合方案集（PP）分析人群73例,将其随机分为两组,A组37例采用莫西沙星注射液400mg,qdivgtt;B组36例采用左氧氟沙星注射液200mg,bidivgtt。运用药物经济学最小成本分析法、成本-效果分析法推算每例治疗成本并进行分析评价。结果两组临床痊愈率和总有效率分别为64.9%、89.2%和63.9%、88.9%,不良反应发生率分别为10.9%和8.7%。治愈每例患者所需药品的最小成本（5386.0±1795.4）元和（2182.2±727.4）元;以临床总有效率计C/E分别为（58.9±19.6）和（35.4±11.8）;ΔC/ΔE为7004。结论虽然莫西沙星疗效优于左氧氟沙星,但根据最小成本法和成本-效果分析表明,左氧氟沙星更具成本-效果优势。

The Evaluation Pharmacoeconomics of Randomized Controlled Test of Moxifloxacin Injection and Levofloxacin Injection in Therapeutic Community Acquired Pneumonia

Objective To evaluate the safety and effectivity of moxifloxacin Injection and levofloxacin Injection in Therapeutic Community Acquired Pneumonia and pharmacoeconomics of the two groups＇ medical cost. Methods Using block randomized, open, parallel controlled design method; with various community acquired pneumonia scheme set （PP） analysis of population in 73 cases, which were randomly divided into two groups, 37 cases in A group with moxifloxacin injection 400mg, QD, IVGTT; B group of 36 cases were treated with levofloxacin injection 200mg, bid ivgtt. Application of pharmacoeconomics cost-minimization analysis, cost-effectiveness analysis method was used to calculate each patients and evaluate the treatment cost. Results Two groups of clinical cure rate and the total rate of 64.9%, 89.2% and 63.9%, 88.9% respectively, the incidence of adverse reaction was 10.9% and 8.7% respectively. The cure to minimize the cost of each patient needed medicine （5386.0±1795.4） and （2182.2±727.4） yuan; to the total clinical effective rate of C/E was （58.9±19.6） and （35.4±11.8）; ΔC/ΔE=7004. Conclusion Although the curative effect of moxifloxacin was better than levofloxacin,according to cost-minimization analysis and cost-effect analysis, levofloxacin had superiority of cost-effect.